Background: Studies evaluating antimicrobial stewardship programmes (ASPs) supported by computerized clinical decision support systems (CDSSs) have predominantly been conducted in single site metropolitan hospitals.
Introduction
Antimicrobial stewardship programmes (ASPs) aim to improve appropriateness of antimicrobial prescribing with the goals of more effectively treating and preventing infections, while curbing antimicrobial resistance and reducing adverse effects. 1, 2 Studies examining the impact of ASPs have primarily been conducted in tertiary metropolitan hospitals. [3] [4] [5] [6] [7] [8] There is limited literature describing clinical outcomes from collaboratively implemented ASPs across multiple hospital sites. [8] [9] [10] [11] Previous single site ASP studies have demonstrated benefits using a computerized clinical decision support system (CDSS), antimicrobial restriction, and prospective audit and feedback. [3] [4] [5] [6] 12 These benefits include a reduction in targeted antimicrobial use, 4, 12, 13 antimicrobial drug acquisition costs, 4, 13, 14 and healthcare-associated Clostridium difficile infection (HCA-CDI) rates. 13, 15 An evidence gap exists for implementation of ASPs across multiple sites using a centrally deployed CDSS. 2 Metrics for evaluating ASPs include antimicrobial use, drug costs, adverse effects such as HCA-CDI and antimicrobial resistance, length of stay (LOS) and mortality. 16, 17 Infection-related outcomes related to community-acquired pneumonia (CAP), skin and soft tissue infections and septicaemia have also been recommended. 16 Although there are confounders associated with their use as ASP metrics, LOS and mortality are useful balancing measures to address potential unintended consequences. 12 To our knowledge, no studies of multisite ASPs using a centrally deployed CDSS have included non-metropolitan hospitals. The aims of this study were to evaluate the impact of a CDSSsupported, multisite ASP on antimicrobial use, antimicrobial costs, HCA-CDI rates, infection-related LOS and standardized mortality ratios (SMRs).
Methods

Setting
In 2012 a multisite ASP supported by a centrally deployed CDSS was implemented in 12 hospital sites ( Figure 1 ) across the South Eastern Sydney and Illawarra Shoalhaven Local Health Districts, and Sydney Children's Hospital, all in New South Wales (NSW), Australia. These districts cover a geographical area of 6331 km 2 and have an estimated population of 1.17 million, extending from central Sydney to around 3 h drive south. 18 Comparable adult metrics were available for analysis in five hospitals, comprising 1900 beds, as shown in Figure 1 . The remaining hospitals were not included in the study for the following reasons: small size, ASP implementation outside of study period, specialist (i.e. obstetrics, paediatrics) or subacute admissions (Figure 1 ). Those attributes would not allow comparison of outcomes such as antimicrobial use, LOS or HCA-CDI. The specialist paediatric hospital contributed to the development of guidelines for paediatric services within the other hospitals. Hospitals shared antimicrobial stewardship strategies, including a centrally deployed CDSS (Guidance MSV R , Melbourne Health 19 ), educational material and similar antimicrobial formulary restrictions. Further information on case complexity and case mix of the included study hospitals is provided in Table S1 (available as Supplementary data at JAC Online).
Intervention
An interrupted time series (ITS) study was conducted combining data from five acute hospitals. The intervention point for the ASP was defined as the go-live date of the CDSS with concurrent dissemination of standardized antimicrobial prescribing guidelines at each site (May-July 2012). This occurred in the setting of a 6 month lead-in period of prior education and antimicrobial guideline development (Figure 1 ). The fully modifiable CDSS, Guidance MSV R , is an intranet browser-based CDSS that guides prescribers on appropriate use and generates approvals for antimicrobials. 19 Antimicrobial restriction (a key component of our ASP) within the CDSS is determined on the basis of spectrum of action, potential toxicity or cost. 19 Implementation of the CDSS used project methodology (PRINCE2V R , ILX Group, Mulgrave, Victoria, Australia) and was overseen by a multidisciplinary committee of medical, pharmacy, information technology and executive staff. The committee met monthly via teleconference and collaborated closely throughout the project implementation period (May 2011 to May 2012). This period was critical to optimize organizational readiness for implementation of a CDSS-supported ASP. 1 Antimicrobial guidelines were based on national guidelines, 20 then standardized across the hospitals and incorporated into the CDSS. The development of guidelines, educational content and decision support was shared by adult and paediatric Infectious Diseases (ID) physicians and antimicrobial stewardship pharmacists. This allowed for a standardized intervention that was tailored to hospital size and level of acuity (Figure 1 ), thereby reducing individual hospital workload, allowing access to clinical expertise at smaller sites and ensuring timely consensus on CDSS clinical content. Staffing (ID physicians, pharmacists and microbiologists) varied across the hospital sites, so intranet-based guidelines and an antimicrobial advice hotline were used to promote access to programme resources. Standardized bimonthly nationally benchmarked antimicrobial usage audits were reported to respective hospital antimicrobial stewardship committees. 21 Prior to the study, antimicrobial stewardship activities were restricted to phone-based advice, formal infectious diseases consults, selective antimicrobial susceptibility reporting, restriction of antifungals and reserve antibacterials (e.g. linezolid, tigecycline, colistin and daptomycin), and a phone-based approval system at one study hospital (Figure 1 ). Study investigators classified the most commonly used antimicrobial classes into two categories, targeted either for increased or for decreased use. Categorization was based on the following factors: local antimicrobial resistance patterns, local use compared with benchmarked hospitals, 21 risk of HCA-CDI and other side effects, compliance with antimicrobial guidelines, 20 and cost. Antimicrobials targeted for increased use were benzylpenicillin, doxycycline and aminopenicillins, whereas antimicrobials targeted for decreased use were third-generation cephalosporins, macrolides, antipseudomonal b-lactam/b-lactamase inhibitor combinations, fluoroquinolones and carbapenems. Additional antimicrobials were targeted for increased use in some settings, but decreased use in others. For example, local quality audits identified underdosing in surgical prophylaxis, but unnecessarily long duration of therapy in other settings such as cellulitis (data not shown). Such antimicrobials (i.e. first-generation cephalosporins, flucloxacillin, aminoglycosides and vancomycin) were included in the overall antimicrobial use analysis.
The infection control policies related to C. difficile and hand hygiene were not subject to any major changes during the study period. Infection control measures recommended by local policies included: isolation in single rooms; use of disposable gowns and gloves; hand hygiene with alcoholbased hand rub and/or soap and water; and terminal cleaning with chlorine-based disinfectant. Diagnostic testing methods for C. difficile were comparable across the health districts' three main laboratories from May 2010, and included first line testing with targeted glutamate dehydrogenase (GDH) antigen and toxins A and B (e.g. C. Diff Quik Chek CompleteV R , Techlab, Blacksburg, VA, USA). Discordant results occasioned the use of a PCR (e.g. GeneXpertV R , Cepheid, Sunnyvale, CA, USA) test. All diarrhoeal stools were subjected to testing from December 2010 (7 months after the beginning of the pre-intervention period).
A subset of the C. difficile data has been published previously in a different context. 22 These data have been included here to allow comparison in the multisite setting.
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Outcomes
The effect of the intervention was assessed by: (i) change in antimicrobials targeted for increased use (benzylpenicillin, doxycycline and aminopenicillins) expressed as defined daily doses (DDDs) per 1000 occupied bed days (OBDs); (ii) change in antimicrobials targeted for decreased use (thirdgeneration cephalosporins, macrolides, anti-pseudomonal b-lactam/ b-lactamase inhibitor combinations, fluoroquinolones and carbapenems; DDDs/1000 OBDs); 22 (iii) change in total monthly antimicrobial costs [Australian dollars (AUD$)]-high cost antifungals (liposomal amphotericin, anidulafungin, caspofungin, posaconazole and voriconazole) were analysed separately to the main antimicrobial group, due to small variations in use accounting for large cost variations; (iv) change in HCA-CDI rates, Figure 1 . Population, clinical setting, nature and timing of interventions. †Phone-based antimicrobial stewardship with formulary restriction was implemented in November 2008. *Exclusions: delayed implementation, hospital sites had delayed recruitment of specialist staff and inadequate reporting of antimicrobial benchmarking data; data not comparable, specialist children's and women's hospitals with non-comparable patient and case mix; small sample size, antimicrobial use and cost data not reported to the NAUSP; CDI, LOS and mortality data were not analysed due to small sample size and high proportion of sub-acute admissions.
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defined as a positive laboratory test for toxigenic C. difficile plus diarrhoea onset greater than 48 h after hospital admission (HCA-CDI cases per 10 000 OBDs); 23 and (v) change in LOS and in-hospital SMR for respiratory tract infections, cellulitis, kidney and urinary tract infections, and septicaemia, compared with background figures for all conditions (infectious and noninfectious combined). Confounders for each of the above measures were also investigated and reported where appropriate. Those included infection outbreaks, updated guidelines, changes to drug acquisition costs and administrative changes.
Data sources
Adult inpatient data were included from May 2010 to July 2014. Antimicrobial use and acquisition cost data were obtained from pharmacy dispensing software, iPharmacyV R Versions 5.5 and 5.6 (CSC, Sydney, Australia). Antimicrobial use data were processed by the National Antimicrobial Utilisation Surveillance Program (NAUSP) 21 using WHO classifications. Occupied bed day data were sourced from the hospitals' performance units. HCA-CDI numbers were provided by the infection control teams in line with standardized surveillance and reporting. 23 LOS (using Australian refined diagnosis related groups 24 ) and SMRs (using principal diagnosis codes, based on International Classification of Diseases, 10th revision, Australian modification 24 ) were provided by the performance units for the following key infections: respiratory infections/inflammations (predominantly pneumonia), cellulitis, and kidney and urinary tract infections. Those were the commonest treatment indications for antimicrobials in the 2014 Australian National Antimicrobial Prescribing Survey (NAPS). 25 Septicaemia was also included due to its high mortality. 26 LOS and SMRs were compared for the periods 1 July 2010-30 June 2012 and 1 July 2012-30 June 2014, as only data aligned with Australian financial years was available. Analysis of overall LOS excluded day case haemodialysis admissions. Comparative case complexity and case mix of the study hospitals was reported using National Weighted Activity Units (NWAUs) 27 and diagnosis-related groups (Table S1 ). 24 
Statistical analyses
ITS analysis with segmented linear regression was used to examine the impact of the intervention on monthly antimicrobial use, costs and HCA-CDI, estimating the immediate effects of the intervention and changes in trend. 28 To account for seasonal variations, 24 time points 1 month apart were used pre-and post-intervention. 14 To allow for statistical analysis of 2 years pre-and 2 years post-intervention, the intervention point (go-live date of CDSS-supported ASP) was aligned for the five hospitals, with individual hospital data included in Tables S2-S11. Definitions for ITS were: (i) initial level, model-predicted level (antimicrobial use, cost, HCA-CDI) 24 months pre-intervention; (ii) initial trend, model-predicted monthly trend pre-intervention; (iii) change in level (immediate effect), modelpredicted difference between the level at the end of the pre-intervention period and commencement of the post-intervention period; 3 and (iv) change in trend, model-predicted difference between initial (pre-intervention) monthly trend and post-intervention trend. Autocorrelation using the Newey-West approximation for standard errors was investigated and an appropriate lag was used when necessary, in order to assess for similarity between observations. 28 LOS was assessed using the Mann-Whitney U-test. A logistic regression model was used to calculate the number of expected deaths using: age; sex; admission type (emergency or acute); admission source (acute transfer or other); principal diagnosis; and Charlson Comorbidity Index (0, 1-2 or 3!). 29 Additional variables used in the expected deaths analysis related to vascular surgery, cardiac surgery, neurosurgery, trauma and transplant. Those figures were then used to calculate infection-related and total SMR (actual deaths/expected deaths). SMRs (pre-and post-intervention) were expressed with 95% CIs. Statistical significance was considered P , 0.05. Statistical analyses were performed using StataV R Statistical Software: Release 14 (Statacorp 2015; College Station, TX, USA).
Ethics
Ethics approval was obtained from the districts' Human Research Ethics Committees, approval number HE13/137.
Results
Antimicrobial use
Following the intervention, a rise in antimicrobials targeted for increased use of 70 DDDs/1000 OBDs (!32%; P , 0.01) was observed, followed by a decline in trend of 3.5 DDDs/1000 OBDs per month (P , 0.01). A concomitant reduction in antimicrobials targeted for decreased use of 58 DDDs/1000 OBDs (#23%; P , 0.01) was observed, followed by a rise in trend of 3.4 DDDs/ 1000 OBDs per month (P , 0.01; Table 1, Figure 2 ). No significant change in level or trend was observed for overall antimicrobial use. There was a national shortage of benzylpenicillin in 2010-11; ampicillin was recommended as an alternative for most benzylpenicillin indications during this period. The national antimicrobial guidelines 20, 30 were updated in 2010 and again in 2014.
Antimicrobial costs
There was a significant reduction in total monthly antimicrobial costs of AUD$64551 (#17%; P , 0.01) post-intervention, followed by an increase in trend of AUD$7273 per month (P , 0.01; Table 2 ). This corresponded to a reduction of AUD$1.70/OBD postintervention (#20%; P , 0.01), with a subsequent increase in trend of AUD$0.26/OBD per month (P , 0.01). High cost antifungals demonstrated an immediate cost reduction (P , 0.01), with no significant increase in trend. Some changes in acquisition costs were noted prior to the intervention, most notably a reduction in meropenem acquisition costs in mid-2011.
HCA-CDI rates
HCA-CDI rates were increasing pre-intervention from 2.8 to 6.2 cases/10 000 OBDs per month (P , 0.01). A reduction was demonstrated post-intervention (#1.2 cases/10 000 OBDs/month, P " 0.15), followed by a decrease in trend (P , 0.01; Table 2 , Figure 3 ). There were no systemic changes to hand hygiene, isolation or cleaning policies during the study period. The rate of hand hygiene compliance had increased across facilities following national initiatives prior to 2009. There were no notable HCA-CDI outbreaks from 2010 to 2014.
LOS
Median LOS was reduced for respiratory infections (from 4.8 to 4.3 days, P , 0.01), cellulitis (3.2 to 2.9 days, P , 0.01), urinary and kidney infections (3.3 to 2.9 days, P , 0.01), and septicaemia (6.8 to 6.1 days, P , 0.01; Table 3 ). Over the same period, median LOS for all hospital admissions also decreased from 2.1 to 1.9 days (P , 0.01). 
Discussion
To our knowledge, this is the first study to evaluate implementation of a multisite ASP supported by a centrally deployed CDSS. We found significant improvements in antimicrobial use, demonstrated by changes in antimicrobials targeted for increased and decreased use. There were significant reductions in antimicrobial costs and HCA-CDI rates. Safety of the intervention was supported by decreased or unchanged LOS and SMRs for key infections during the study period. The long-term impact of the intervention on antimicrobial use and cost diminished over time, which suggests that ongoing programme reinforcement and targeted interventions may be required to alleviate 'antimicrobial stewardship fatigue'. Changes in overall antimicrobial use prior to the main intervention probably resulted from an intensive education campaign to optimize appropriate antimicrobial use across the hospitals, with heightened awareness of the impending change among clinicians. The importance of readiness assessments prior to implementation was recognized, along with shared interventions across the study hospitals. Those included antimicrobial stewardship ward rounds with post-prescription review and feedback, consensus guidelines, departmental education, and antimicrobial restriction. Some studies have evaluated ASPs across multiple hospital sites 8, 9, 31 and the utility of an individual site CDSS for improvement in antimicrobial prescribing; 3, [32] [33] [34] however, the combination of these two approaches is novel. Furthermore, this collaborative ASP was applied to non-metropolitan settings with an established structure of support from a larger hospital. Pooling data across five hospitals enhanced the potential to identify effects of the ASP. Few randomized studies have been conducted to determine the effect of ASPs. 8, 12 Our study used ITS analysis, which is considered an alternative pragmatic approach with strong quasi-experimental design. 35 Comparison with control hospitals would have strengthened the study design; however, none was available in the health districts due to widespread implementation of the ASP.
Our study demonstrates that shared knowledge and expertise can be used to effectively implement an ASP across multiple hospital sites spanning a wide geographical area. The economies of scale enjoyed by the multisite approach allowed for collective interventions to be employed with reduced workload at individual hospital sites. Multisite implementation also alleviated some of the potential disadvantages of the CDSS, such as resources required for implementation and maintenance. 2 An additional benefit of extensive multisite intervention was consistency in antimicrobial prescribing guidelines, facilitating the training of medical officers rotating through the facilities within the districts' different hospitals. A consistent, multisite approach was also anticipated to enhance prescriber confidence and facilitate the quality improvement culture necessary to effect longer term improvements in antimicrobial prescribing. 36, 37 ASPs are a key element of the approach to reducing HCA-CDI. 38 Importantly, our intervention was associated with a reduction in HCA-CDI rates, as well as a decrease in trend that persisted over time. This occurred in the context of increasing community CDI rates. 39 The specialist paediatric hospital and paediatric wards from study sites were not included in this analysis. Non-comparability of standard adult metrics such as DDDs results in difficulty benchmarking antimicrobial use in children. 40 HCA-CDI cannot easily be assessed in the paediatric population due to asymptomatic carriage in infants and lower rates of symptomatic CDI in children. 41 Although quantitative paediatric data were not included in this Bond et al.
study, paediatric antimicrobial guidelines and CDSS development were important for multisite ASP implementation across the network of small rural to large metropolitan hospitals. Maintaining cost effectiveness is of concern to administrators. 42 Placing drug costs as the primary measure of cost analysis does not take into account changes in acquisition costs (e.g. when drugs come off patent). In addition, the most appropriate antimicrobial is not necessarily the lowest in price. Identifying other methods of cost-benefit analysis is justified, such as the impact of healthcareassociated infections, and the increased cost of treating resistant organisms. 43 Some cost savings were attributed to reductions in drug acquisition costs, such as for meropenem in 2011. Paradoxically, the intervention was associated with increased drug costs in some instances. Benzylpenicillin, targeted for increased use, had a daily cost at usual dosing (1.2 g intravenously every 6 h) of AUD$25, compared with ceftriaxone (targeted for decreased use; AUD$1.30 for 1 g intravenously daily). In addition, the postintervention cost increase may have been driven by high cost antifungal use where treatment of a small number of patients may result in a significant increase in drug costs. Building works at some of the sites, leading to increased prophylaxis and treatment of invasive fungal infections, may have led to this increase. However, antifungals were not a main target of the collaborative ASP as they were already highly restricted prior to the intervention. Costs of the intervention were not analysed as part of this study; there were costs associated with purchasing the CDSS, and additional pharmacy and ID resources in supporting the ASPs.
There were some other limitations to this study. Antimicrobial use patterns may also have been affected by unforeseen drug shortages and changes to infection control practices. There were no systematic changes to the infection control policies across the districts during the study period, and no recognized outbreaks of CDI occurred during this time. Some measures were not included due to a lack of comparable pre-and post-intervention data across sites; these included the impact of antimicrobial stewardship ward rounds, point prevalence survey results and antimicrobial resistance patterns. Antimicrobials analysed included only those targeted for increased (e.g. benzylpenicillin) or decreased (e.g. ceftriaxone) use. Not all antimicrobial classes were reported individually, such as glycopeptides (e.g. vancomycin) and firstgeneration cephalosporins (e.g. cefazolin, cefalexin). Although often targeted in ASPs, based on national guidelines 20 there were instances where these classes were targeted for either increased or decreased use. As such, it was not clear whether the ASP would result in a change to use. Reserve antibacterial agents such as linezolid and daptomycin were already highly restricted prior to the intervention, requiring prior physician approval before use.
The effect of the intervention was not uniform across the sites. Reasons for this variability may have included differences in maturity of existing antimicrobial stewardship initiatives prior to the introduction of the CDSS, disparate levels of acuity and variable patterns of resistance. Pre-existing antimicrobial stewardship initiatives at all sites consisted of selective microbiology reporting, limited ID and microbiology phone support, and some departmental education, with one site additionally using a phone-based approval system (Figure 1 ). Variation in case complexity and case mix between study hospitals (Table S1 ) may have justified some differences in antimicrobial use. Additionally, seasonal variation was evident in the antimicrobial use patterns. Those confounders may Multisite antimicrobial stewardship JAC have been alleviated by using combined antimicrobial use data with sufficient pre-and post-intervention time points for the ITS analysis. Data on antimicrobial use, cost and HCA-CDI could not be aligned perfectly in time with LOS and mortality data due to report limitations; however, the maximum lag (for one hospital) was only 6 weeks over a 48 month period. Infection-related and overall LOS decreased after the intervention, which may have been due to increased use of hospital in the home services. There may have been potential confounders, such as changes to funding and hospital admission models that affected LOS and SMR during the intervention, which were difficult to quantify. However, LOS and SMR were included as important balancing measures as they could potentially be negatively impacted by changed patterns of antimicrobial use. State-wide programmes were also introduced by the New South Wales Clinical Excellence Commission from 2010-2014 to improve management of deteriorating patients (Between the Flags programme) and recognition and management of sepsis (Sepsis Kills programme). 44 Those initiatives potentially contributed to the improvements in LOS and SMR in the post-intervention period.
We anticipate that our findings would be generalizable to healthcare facilities with potential for utilizing shared resources, such as those with existing professional or political networks. Additional studies using prospective methodological approaches in different settings would help to validate our results.
Conclusion
Implementation of a multisite ASP supported by a centrally deployed CDSS was associated with significant changes to targeted antimicrobial use, containment of antimicrobial expenditure and reduction in HCA-CDI, without obvious adverse effects. Ongoing targeted interventions involving education and behaviour change are required to sustain the benefits of ASPs on hospital antimicrobial use.
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